Unity Biotechnology Inc appoints Yehia Hashad, MD, to the board of directors and science committee
Hashad is a retinal specialist with over 25 years of leadership experience in global research and development.
(Image credit: AdobeStock/stardadw007)
Yehia Hashad, MD, has been appointed to the board of directors and as a member of its science committee for Unity Biotechnology Inc.
In the company’s press release1, Anirvan Ghosh, PhD, chief executive officer of UNITY Biotechnology spoke to Hashad’s qualification and experience, saying, "Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to potentially advance UBX1325 to late-stage development. With over two decades of experience in clinical and commercial drug development, Dr. Hashad’s insights will be instrumental in positioning UBX1325 as a much-needed treatment option for patients with diabetic macular edema."
Hashad himself is quoted in the news release1 as well. He said, "I am thrilled to join UNITY at this pivotal moment and contribute to its mission to develop the next generation of therapeutics for retinal diseases. I look forward to collaborating with the UNITY team to advance the lead senolytic program and shape an exciting pipeline of future products."
Unity Biotechnology shared a brief biography on Hashad’s past positions and notable achievements, as follows: Hashad is a retinal specialist with over 25 years of leadership experience in global research and development. In his current position as the executive vice president of research & development and chief medical officer at Bausch + Lomb, he oversees all R&D portfolios across all business units. Previously, he served as senior vice president and head of R&D for Allergan Aesthetics (Abbvie Company), in which he oversaw the development of more than 40 programs that spanned a wide range of pharmaceutical products. Prior to Allergan, Hashad spent five years with Novartis Pharma AG, where he served as a global medical director for age-related macular degeneration-related treatments Visudyne and Lucentis and as a medical director, ophthalmology for the European region. Hashad obtained his Master of Science in medical and surgical ophthalmology from Cairo University and a business degree from INSEAD in France. He previously served on the boards of The Glaucoma Research Foundation, the National Alliance of Eye and Vision Research, and the University of California Irvine Research Center.1
